BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brisbare-roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13:150-5. [DOI: 10.1038/nm1544] [Cited by in Crossref: 396] [Cited by in F6Publishing: 371] [Article Influence: 26.4] [Reference Citation Analysis]
Number Citing Articles
1 Bergman JM, Roecker AJ, Mercer SP, Bednar RA, Reiss DR, Ransom RW, Meacham Harrell C, Pettibone DJ, Lemaire W, Murphy KL, Li C, Prueksaritanont T, Winrow CJ, Renger JJ, Koblan KS, Hartman GD, Coleman PJ. Proline bis-amides as potent dual orexin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2008;18:1425-30. [DOI: 10.1016/j.bmcl.2008.01.001] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
2 Martin EJ, Hernandez ME, Hayward LF. Blockade of orexin receptors attenuates the cardiovascular response to air-jet stress in spontaneously hypertensive rats. Auton Neurosci 2016;201:8-16. [PMID: 27591948 DOI: 10.1016/j.autneu.2016.08.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
3 Camarda V, Rizzi A, Ruzza C, Zucchini S, Marzola G, Marzola E, Guerrini R, Salvadori S, Reinscheid RK, Regoli D, Calò G. In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther 2009;328:549-55. [PMID: 18971372 DOI: 10.1124/jpet.108.143867] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
4 Mould R, Brown J, Marshall FH, Langmead CJ. Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands. Br J Pharmacol 2014;171:351-63. [PMID: 23692283 DOI: 10.1111/bph.12245] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
5 Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S, Träskman-Bendz L, Goddard AW, Brundin L, Shekhar A. A key role for orexin in panic anxiety. Nat Med. 2010;16:111-115. [PMID: 20037593 DOI: 10.1038/nm.2075] [Cited by in Crossref: 247] [Cited by in F6Publishing: 229] [Article Influence: 19.0] [Reference Citation Analysis]
6 Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, Roche O, Rogers-Evans M, Wettstein JG, Moreau JL. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol 2009;156:1326-41. [PMID: 19751316 DOI: 10.1111/j.1476-5381.2009.00127.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
7 Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 2014;171:283-93. [PMID: 23731216 DOI: 10.1111/bph.12261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 10.8] [Reference Citation Analysis]
8 Boss C, Roch C. Orexin research: patent news from 2016. Expert Opinion on Therapeutic Patents 2017;27:1123-33. [DOI: 10.1080/13543776.2017.1344221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
9 Roundtree HM, Simeone TA, Johnson C, Matthews SA, Samson KK, Simeone KA. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice. Sleep 2016;39:357-68. [PMID: 26446112 DOI: 10.5665/sleep.5444] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Oi N, Suzuki M, Terauchi T, Tokunaga M, Nakatani Y, Yamamoto N, Fukumura T, Zhang M, Suhara T, Higuchi M. Synthesis and Evaluation of Novel Radioligands for Positron Emission Tomography Imaging of the Orexin-2 Receptor. J Med Chem 2013;56:6371-85. [DOI: 10.1021/jm400772t] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
11 Aissaoui H, Koberstein R, Zumbrunn C, Gatfield J, Brisbare-roch C, Jenck F, Treiber A, Boss C. N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2008;18:5729-33. [DOI: 10.1016/j.bmcl.2008.09.079] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
12 Dugovic C, Shelton JE, Yun S, Bonaventure P, Shireman BT, Lovenberg TW. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front Neurosci 2014;8:28. [PMID: 24592208 DOI: 10.3389/fnins.2014.00028] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
13 Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep 2020;43:zsaa080. [PMID: 32303763 DOI: 10.1093/sleep/zsaa080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Dingemanse J, Cruz HG, Gehin M, Hoever P. Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem. J Pharm Sci 2014;103:1548-56. [PMID: 24604243 DOI: 10.1002/jps.23916] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
15 Williams KS, Diniz Behn CG. Dynamic Interactions between Orexin and Dynorphin May Delay Onset of Functional Orexin Effects: A Modeling Study. J Biol Rhythms 2011;26:171-81. [DOI: 10.1177/0748730410395471] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
16 Bai P, Liu Y, Xu Y, Striar R, Yuan G, Afshar S, Langan AG, Rattray AK, Wang C. Synthesis and characterization of a new Positron emission tomography probe for orexin 2 receptors neuroimaging. Bioorg Chem 2022;123:105779. [PMID: 35397430 DOI: 10.1016/j.bioorg.2022.105779] [Reference Citation Analysis]
17 Han F. Narcolepsy, orexins and respiratory regulation: Respiratory regulation in narcolepsy. Sleep and Biological Rhythms 2011;9:44-51. [DOI: 10.1111/j.1479-8425.2010.00467.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Vazquez-DeRose J, Schwartz MD, Nguyen AT, Warrier DR, Gulati S, Mathew TK, Neylan TC, Kilduff TS. Hypocretin/orexin antagonism enhances sleep-related adenosine and GABA neurotransmission in rat basal forebrain. Brain Struct Funct 2016;221:923-40. [PMID: 25431268 DOI: 10.1007/s00429-014-0946-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
19 Equihua AC, De La Herrán-Arita AK, Drucker-Colin R. Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol 2013;4:163. [PMID: 24416019 DOI: 10.3389/fphar.2013.00163] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
20 Boss C. Orexin receptor antagonists--a patent review (2010 to August 2014). Expert Opin Ther Pat 2014;24:1367-81. [PMID: 25407283 DOI: 10.1517/13543776.2014.978859] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
21 Kumar A, Chanana P, Choudhary S. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs. Pharmacological Reports 2016;68:231-42. [DOI: 10.1016/j.pharep.2015.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
22 Puerto Galvis CE, Kouznetsov VV. Novel Approaches in the Synthesis of Natural and Synthetic Fused Aza-Polycycles Toward the Development of New Bioactive Compounds. Elsevier; 2018. pp. 1-51. [DOI: 10.1016/b978-0-444-64058-1.00001-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 2014;9:311-22. [PMID: 24376006 DOI: 10.1002/cmdc.201300447] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
24 Thomasy HE, Febinger HY, Ringgold KM, Gemma C, Opp MR. Hypocretinergic and cholinergic contributions to sleep-wake disturbances in a mouse model of traumatic brain injury. Neurobiol Sleep Circadian Rhythms 2017;2:71-84. [PMID: 31236496 DOI: 10.1016/j.nbscr.2016.03.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
25 Wu MF, Nienhuis R, Maidment N, Lam HA, Siegel JM. Role of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy. J Neurosci 2011;31:6305-10. [PMID: 21525270 DOI: 10.1523/JNEUROSCI.0365-11.2011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
26 Stettner GM, Kubin L. Antagonism of orexin receptors in the posterior hypothalamus reduces hypoglossal and cardiorespiratory excitation from the perifornical hypothalamus. J Appl Physiol (1985) 2013;114:119-30. [PMID: 23104701 DOI: 10.1152/japplphysiol.00965.2012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
27 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Yi SS, Chung SH, Kim PS. Sharing Pathological Mechanisms of Insomnia and Osteoporosis, and a New Perspective on Safe Drug Choice. J Menopausal Med 2018;24:143-9. [PMID: 30671405 DOI: 10.6118/jmm.2018.24.3.143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Iigaya K, Horiuchi J, Mcdowall LM, Lam ACB, Sediqi Y, Polson JW, Carrive P, Dampney RAL. Blockade of orexin receptors with Almorexant reduces cardiorespiratory responses evoked from the hypothalamus but not baro- or chemoreceptor reflex responses. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2012;303:R1011-22. [DOI: 10.1152/ajpregu.00263.2012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
30 Deporter DP, Coborn JE, Teske JA. Partial Sleep Deprivation Reduces the Efficacy of Orexin-A to Stimulate Physical Activity and Energy Expenditure: Sleep Deprivation Dampens EE During Physical Activity. Obesity 2017;25:1716-22. [DOI: 10.1002/oby.21944] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
31 Fujimoto T, Tomata Y, Kunitomo J, Hirozane M, Marui S. Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2011;21:6409-13. [DOI: 10.1016/j.bmcl.2011.08.094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
32 Morairty SR, Wilk AJ, Lincoln WU, Neylan TC, Kilduff TS. The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats. Front Neurosci 2014;8:3. [PMID: 24550767 DOI: 10.3389/fnins.2014.00003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
33 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
34 Malherbe P, Roche O, Marcuz A, Kratzeisen C, Wettstein JG, Bissantz C. Mapping the Binding Pocket of Dual Antagonist Almorexant to Human Orexin 1 and Orexin 2 Receptors: Comparison with the Selective OX 1 Antagonist SB-674042 and the Selective OX 2 Antagonist N -Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]- N -pyridin-3-ylmethyl-acetamide (EMPA). Mol Pharmacol 2010;78:81-93. [DOI: 10.1124/mol.110.064584] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
35 Silva C, Mcnaughton N. Are periaqueductal gray and dorsal raphe the foundation of appetitive and aversive control? A comprehensive review. Progress in Neurobiology 2019;177:33-72. [DOI: 10.1016/j.pneurobio.2019.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
36 Wesensten NJ, Hughes JD, Balkin TJ. Countermeasures to the neurocognitive deficits associated with sleep loss. Drug Discovery Today: Disease Models 2011;8:139-46. [DOI: 10.1016/j.ddmod.2011.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
37 Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G. Multiple roles for orexin/hypocretin in addiction. Prog Brain Res 2012;198:79-121. [PMID: 22813971 DOI: 10.1016/B978-0-444-59489-1.00007-0] [Cited by in Crossref: 140] [Cited by in F6Publishing: 76] [Article Influence: 14.0] [Reference Citation Analysis]
38 Yeoh JW, Campbell EJ, James MH, Graham BA, Dayas CV. Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls. Front Neurosci 2014;8:36. [PMID: 24616658 DOI: 10.3389/fnins.2014.00036] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
39 Nair SG, Golden SA, Shaham Y. Differential effects of the hypocretin 1 receptor antagonist SB 334867 on high-fat food self-administration and reinstatement of food seeking in rats. Br J Pharmacol 2008;154:406-16. [PMID: 18223663 DOI: 10.1038/bjp.2008.3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 105] [Article Influence: 7.2] [Reference Citation Analysis]
40 Anderson RI, Becker HC, Adams BL, Jesudason CD, Rorick-Kehn LM. Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models. Front Neurosci 2014;8:33. [PMID: 24616657 DOI: 10.3389/fnins.2014.00033] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 6.0] [Reference Citation Analysis]
41 Hoyer D, Bartfai T. Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach. Chem Biodivers 2012;9:2367-87. [PMID: 23161624 DOI: 10.1002/cbdv.201200288] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
42 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
43 Prince CD, Rau AR, Yorgason JT, España RA. Hypocretin/Orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by hypocretin receptor 1. ACS Chem Neurosci 2015;6:138-46. [PMID: 25496218 DOI: 10.1021/cn500246j] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
44 Grunstein R, Han F. Twenty-five years of Respirology: Advances in sleep. Respirology 2020;25:41-2. [PMID: 31840888 DOI: 10.1111/resp.13741] [Reference Citation Analysis]
45 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 McGaughey G, Bayly CI, Cox CD, Schreier JD, Breslin MJ, Bogusky M, Pitzenberger S, Ball R, Coleman PJ. Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs. J Comput Aided Mol Des 2014;28:5-12. [PMID: 24488306 DOI: 10.1007/s10822-014-9710-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
47 Xu L, Krishna A, Stewart S, Shea K, Racz R, Weaver JL, Volpe DA, Pilli NR, Narayanasamy S, Florian J, Patel V, Matta MK, Stone MB, Zhu H, Davis MC, Strauss DG, Rouse R. Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat. Clin Transl Sci 2021. [PMID: 34080766 DOI: 10.1111/cts.13080] [Reference Citation Analysis]
48 Boss C, Roch-brisbare C, Steiner MA, Treiber A, Dietrich H, Jenck F, von Raumer M, Sifferlen T, Brotschi C, Heidmann B, Williams JT, Aissaoui H, Siegrist R, Gatfield J. Structure-Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT-462206: a Potent, Brain-Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist. ChemMedChem 2014;9:2486-96. [DOI: 10.1002/cmdc.201402258] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
49 Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 2014;7:711-30. [PMID: 25318834 DOI: 10.1586/17512433.2014.966813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
50 Rasmussen K, Hsu MA, Noone S, Johnson BG, Thompson LK, Hemrick-Luecke SK. The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. Schizophr Bull 2007;33:1291-7. [PMID: 17660489 DOI: 10.1093/schbul/sbm087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
51 Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC Neurosci 2014;15:109. [PMID: 25242351 DOI: 10.1186/1471-2202-15-109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
52 Teske J, Billington C, Kotz C. Neuropeptidergic Mediators of Spontaneous Physical Activity and Non-Exercise Activity Thermogenesis. Neuroendocrinology 2008;87:71-90. [DOI: 10.1159/000110802] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
53 Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, Yao L, Kuduk SD, Uslaner J, Coleman PJ, Renger JJ. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci 2013;14:90. [PMID: 23981345 DOI: 10.1186/1471-2202-14-90] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
54 Dömling A, Wang W, Wang K. Chemistry and biology of multicomponent reactions. Chem Rev 2012;112:3083-135. [PMID: 22435608 DOI: 10.1021/cr100233r] [Cited by in Crossref: 1512] [Cited by in F6Publishing: 1032] [Article Influence: 151.2] [Reference Citation Analysis]
55 Urstadt KR, Coop SH, Banuelos BD, Stanley BG. Behaviorally specific versus non-specific suppression of accumbens shell-mediated feeding by ipsilateral versus bilateral inhibition of the lateral hypothalamus. Behav Brain Res 2013;257:230-41. [PMID: 24100119 DOI: 10.1016/j.bbr.2013.09.048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
56 Nixon JP, Kotz CM, Novak CM, Billington CJ, Teske JA. Neuropeptides controlling energy balance: orexins and neuromedins. Handb Exp Pharmacol 2012;:77-109. [PMID: 22249811 DOI: 10.1007/978-3-642-24716-3_4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
57 Shivshankar P, Fekry B, Eckel-Mahan K, Wetsel RA. Circadian Clock and Complement Immune System-Complementary Control of Physiology and Pathology? Front Cell Infect Microbiol 2020;10:418. [PMID: 32923410 DOI: 10.3389/fcimb.2020.00418] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
58 Teske JA, Billington CJ, Kotz CM. Mechanisms underlying obesity resistance associated with high spontaneous physical activity. Neuroscience 2014;256:91-100. [PMID: 24161277 DOI: 10.1016/j.neuroscience.2013.10.028] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
59 Severs L, Vlemincx E, Ramirez J. The psychophysiology of the sigh: I: The sigh from the physiological perspective. Biological Psychology 2022. [DOI: 10.1016/j.biopsycho.2022.108313] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Hoyer D, Jacobson LH. Orexin Receptor Antagonists. Curr Sleep Medicine Rep 2017;3:342-53. [DOI: 10.1007/s40675-017-0099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 España RA, Scammell TE. Sleep neurobiology from a clinical perspective. Sleep 2011;34:845-58. [PMID: 21731134 DOI: 10.5665/SLEEP.1112] [Cited by in Crossref: 81] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
62 Ueno T, Ishida T, Aluri J, Suzuki M, Beuckmann CT, Kameyama T, Asakura S, Kusano K. Disposition and Metabolism of [ 14 C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites. Drug Metab Dispos 2020;49:31-8. [DOI: 10.1124/dmd.120.000229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
63 Tsuneki H, Sasaoka T, Sakurai T. Sleep Control, GPCRs, and Glucose Metabolism. Trends Endocrinol Metab 2016;27:633-42. [PMID: 27461005 DOI: 10.1016/j.tem.2016.06.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
64 Boof ML, Dingemanse J, Brunke M, Esselmann A, Heymer P, Kestermann O, Lederer K, Fietze I, Ufer M. Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. J Sleep Res 2021;30:e13248. [PMID: 33417730 DOI: 10.1111/jsr.13248] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Qi X, Astle J, Kodadek T. Rapid identification of orexin receptor binding ligands using cell-based screening accelerated with magnetic beads. Mol Biosyst 2010;6:102-7. [PMID: 20024071 DOI: 10.1039/b915611a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
66 Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, Roecker AJ, Mercer SP, Bednar RA, Lemaire W, Bruno JG, Reiss DR, Harrell CM, Murphy KL, Garson SL, Doran SM, Prueksaritanont T, Anderson WB, Tang C, Roller S, Cabalu TD, Cui D, Hartman GD, Young SD, Koblan KS, Winrow CJ, Renger JJ, Coleman PJ. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010;53:5320-32. [PMID: 20565075 DOI: 10.1021/jm100541c] [Cited by in Crossref: 242] [Cited by in F6Publishing: 217] [Article Influence: 20.2] [Reference Citation Analysis]
67 Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1063-78. [DOI: 10.1080/17425255.2020.1817380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
68 Holland P, Goadsby PJ. The Hypothalamic Orexinergic System: Pain and Primary Headaches. Headache: The Journal of Head and Face Pain 2007;47:951-62. [DOI: 10.1111/j.1526-4610.2007.00842.x] [Cited by in Crossref: 128] [Cited by in F6Publishing: 105] [Article Influence: 8.5] [Reference Citation Analysis]
69 Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, Renger JJ, Winrow CJ. Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Front Neurosci 2013;7:254. [PMID: 24399926 DOI: 10.3389/fnins.2013.00254] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
70 Hassani OK, Lee MG, Jones BE. Melanin-concentrating hormone neurons discharge in a reciprocal manner to orexin neurons across the sleep-wake cycle. Proc Natl Acad Sci U S A 2009;106:2418-22. [PMID: 19188611 DOI: 10.1073/pnas.0811400106] [Cited by in Crossref: 289] [Cited by in F6Publishing: 267] [Article Influence: 22.2] [Reference Citation Analysis]
71 Parks GS, Warrier DR, Dittrich L, Schwartz MD, Palmerston JB, Neylan TC, Morairty SR, Kilduff TS. The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems. Neuropsychopharmacology 2016;41:1144-55. [PMID: 26289145 DOI: 10.1038/npp.2015.256] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
72 Matsuki T, Sakurai T. Orexins and Orexin Receptors: From Molecules to Integrative Physiology. In: Civelli O, Zhou Q, editors. Orphan G Protein-Coupled Receptors and Novel Neuropeptides. Berlin: Springer Berlin Heidelberg; 2008. pp. 27-55. [DOI: 10.1007/400_2007_047] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Reference Citation Analysis]
73 Choi Y, Raymer BK. Sleep modulating agents. Bioorg Med Chem Lett 2019;29:2025-33. [PMID: 31307886 DOI: 10.1016/j.bmcl.2019.06.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
74 Gatfield J, Brisbare-Roch C, Jenck F, Boss C. Orexin receptor antagonists: a new concept in CNS disorders? ChemMedChem 2010;5:1197-214. [PMID: 20544785 DOI: 10.1002/cmdc.201000132] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 5.0] [Reference Citation Analysis]
75 Oishi M, Kushikata T, Niwa H, Yakoshi C, Ogasawara C, Calo G, Guerrini R, Hirota K. Endogenous neuropeptide S tone influences sleep-wake rhythm in rats. Neurosci Lett 2014;581:94-7. [PMID: 25161123 DOI: 10.1016/j.neulet.2014.08.031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
76 Dingemanse J, Hoever P. Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects. Drugs R D 2013;13:145-51. [PMID: 23737453 DOI: 10.1007/s40268-013-0017-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
77 Hoch M, Hoever P, Haschke M, Krähenbühl S, Dingemanse J. Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects. J Clin Pharmacol 2011;51:1116-21. [PMID: 20852003 DOI: 10.1177/0091270010377634] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
78 Dingemanse J, Hoever P, Hoch M, Treiber A, Wagner-redeker W, Miraval T, Hopfgartner G, Shakeri-nejad K. Elucidation of the Metabolic Pathways and the Resulting Multiple Metabolites of Almorexant, a Dual Orexin Receptor Antagonist, in Humans. Drug Metab Dispos 2013;41:1046-59. [DOI: 10.1124/dmd.112.050120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
79 Cole AG, Stroke IL, Qin L, Hussain Z, Simhadri S, Brescia M, Waksmunski FS, Strohl B, Tellew JE, Williams JP, Saunders J, Appell KC, Henderson I, Webb ML. Synthesis of (3,4-dimethoxyphenoxy)alkylamino acetamides as orexin-2 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2008;18:5420-3. [DOI: 10.1016/j.bmcl.2008.09.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
80 Tarasiuk A, Levi A, Berdugo-Boura N, Yahalom A, Segev Y. Role of orexin in respiratory and sleep homeostasis during upper airway obstruction in rats. Sleep 2014;37:987-98. [PMID: 24790278 DOI: 10.5665/sleep.3676] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
81 Sakurai T, Mieda M. Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci 2011;32:451-62. [PMID: 21565412 DOI: 10.1016/j.tips.2011.03.007] [Cited by in Crossref: 139] [Cited by in F6Publishing: 136] [Article Influence: 12.6] [Reference Citation Analysis]
82 Hoever P, Hay J, Rad M, Cavallaro M, van Gerven JM, Dingemanse J. Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Almorexant, an Orexin Receptor Antagonist, in Healthy Elderly Subjects. Journal of Clinical Psychopharmacology 2013;33:363-70. [DOI: 10.1097/jcp.0b013e31828f5a7a] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Latifi B, Adamantidis A, Bassetti C, Schmidt MH. Sleep-Wake Cycling and Energy Conservation: Role of Hypocretin and the Lateral Hypothalamus in Dynamic State-Dependent Resource Optimization. Front Neurol 2018;9:790. [PMID: 30344503 DOI: 10.3389/fneur.2018.00790] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
84 Perin M, Longordo F, Massonnet C, Welker E, Lüthi A. Diurnal inhibition of NMDA-EPSCs at rat hippocampal mossy fibre synapses through orexin-2 receptors. J Physiol 2014;592:4277-95. [PMID: 25085886 DOI: 10.1113/jphysiol.2014.272757] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
85 Uslaner JM, Tye SJ, Eddins DM, Wang X, Fox SV, Savitz AT, Binns J, Cannon CE, Garson SL, Yao L, Hodgson R, Stevens J, Bowlby MR, Tannenbaum PL, Brunner J, Mcdonald TP, Gotter AL, Kuduk SD, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 2013;5:179ra44. [PMID: 23552372 DOI: 10.1126/scitranslmed.3005213] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
86 Furlong TM, Vianna DM, Liu L, Carrive P. Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur J Neurosci 2009;30:1603-14. [PMID: 19811530 DOI: 10.1111/j.1460-9568.2009.06952.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 118] [Article Influence: 8.7] [Reference Citation Analysis]
87 Sullivan S. Update on emerging drugs for insomnia. Expert Opinion on Emerging Drugs 2012;17:295-8. [DOI: 10.1517/14728214.2012.693158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
88 Christopher JA. Small-molecule antagonists of the orexin receptors. Pharm Pat Anal 2014;3:625-38. [PMID: 25489915 DOI: 10.4155/ppa.14.46] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
89 Watanabe H, Fukui K, Shimizu Y, Idoko Y, Nakamoto Y, Togashi K, Saji H, Ono M. Synthesis and biological evaluation of F-18 labeled tetrahydroisoquinoline derivatives targeting orexin 1 receptor. Bioorganic & Medicinal Chemistry Letters 2019;29:1620-3. [DOI: 10.1016/j.bmcl.2019.04.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
90 Steiner MA, Lecourt H, Jenck F. The brain orexin system and almorexant in fear-conditioned startle reactions in the rat. Psychopharmacology (Berl) 2012;223:465-75. [PMID: 22592903 DOI: 10.1007/s00213-012-2736-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
91 Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci 2011;31:6518-26. [PMID: 21525292 DOI: 10.1523/JNEUROSCI.6506-10.2011] [Cited by in Crossref: 134] [Cited by in F6Publishing: 78] [Article Influence: 12.2] [Reference Citation Analysis]
92 Sifferlen T, Boller A, Chardonneau A, Cottreel E, Hoecker J, Aissaoui H, Williams JT, Brotschi C, Heidmann B, Siegrist R, Gatfield J, Treiber A, Brisbare-roch C, Jenck F, Boss C. Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure–activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1. Bioorganic & Medicinal Chemistry Letters 2014;24:1201-8. [DOI: 10.1016/j.bmcl.2013.12.092] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
93 Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 2009;61:162-76. [PMID: 19549926 DOI: 10.1124/pr.109.001321] [Cited by in Crossref: 314] [Cited by in F6Publishing: 284] [Article Influence: 26.2] [Reference Citation Analysis]
94 Rihel J, Schier AF. Sites of action of sleep and wake drugs: insights from model organisms. Curr Opin Neurobiol 2013;23:831-40. [PMID: 23706898 DOI: 10.1016/j.conb.2013.04.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
95 Lefter R, Cojocariu RO, Ciobica A, Balmus I, Mavroudis I, Kis A. Interactions between Sleep and Emotions in Humans and Animal Models. Medicina 2022;58:274. [DOI: 10.3390/medicina58020274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Morairty SR, Revel FG, Malherbe P, Moreau JL, Valladao D, Wettstein JG, Kilduff TS, Borroni E. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One 2012;7:e39131. [PMID: 22768296 DOI: 10.1371/journal.pone.0039131] [Cited by in Crossref: 79] [Cited by in F6Publishing: 89] [Article Influence: 7.9] [Reference Citation Analysis]
97 Sun H, Yee KL, Gill S, Liu W, Li X, Panebianco D, Mangin E, Morrison D, McCrea J, Wagner JA, Troyer MD. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects. J Psychopharmacol 2015;29:1159-69. [PMID: 26464455 DOI: 10.1177/0269881115609015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
98 Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, Dingemanse J. Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant. Clin Pharmacol Ther 2010;87:593-600. [DOI: 10.1038/clpt.2010.19] [Cited by in Crossref: 81] [Cited by in F6Publishing: 77] [Article Influence: 6.8] [Reference Citation Analysis]
99 Hoyer D, Allen A, Jacobson LH. Hypnotics with novel modes of action. Br J Clin Pharmacol 2020;86:244-9. [PMID: 31756268 DOI: 10.1111/bcp.14180] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
100 Landry I, Nakai K, Ferry J, Aluri J, Hall N, Lalovic B, Moline ML. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults. Clin Pharmacol Drug Dev 2021;10:153-65. [PMID: 32468649 DOI: 10.1002/cpdd.817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
101 Born S, Gauvin DV, Mukherjee S, Briscoe R. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol 2017;86:181-92. [PMID: 28279667 DOI: 10.1016/j.yrtph.2017.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
102 Perentos N, Martins AQ, Cumming RJ, Mitchell NL, Palmer DN, Sawiak SJ, Morton AJ. An EEG Investigation of Sleep Homeostasis in Healthy and CLN5 Batten Disease Affected Sheep. J Neurosci 2016;36:8238-49. [PMID: 27488642 DOI: 10.1523/JNEUROSCI.4295-15.2016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
103 Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J. Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol 2012;26:1071-80. [DOI: 10.1177/0269881112448946] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
104 Chellappa SL, Schröder C, Cajochen C. Chronobiology, excessive daytime sleepiness and depression: Is there a link? Sleep Medicine 2009;10:505-14. [DOI: 10.1016/j.sleep.2008.05.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
105 Li J, Hu Z, de Lecea L. The hypocretins/orexins: integrators of multiple physiological functions. Br J Pharmacol 2014;171:332-50. [PMID: 24102345 DOI: 10.1111/bph.12415] [Cited by in Crossref: 153] [Cited by in F6Publishing: 141] [Article Influence: 19.1] [Reference Citation Analysis]
106 Quarta D, Valerio E, Hutcheson DM, Hedou G, Heidbreder C. The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization. Neurochemistry International 2010;56:11-5. [DOI: 10.1016/j.neuint.2009.08.012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
107 McGregor R, Wu MF, Barber G, Ramanathan L, Siegel JM. Highly specific role of hypocretin (orexin) neurons: differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level. J Neurosci 2011;31:15455-67. [PMID: 22031892 DOI: 10.1523/JNEUROSCI.4017-11.2011] [Cited by in Crossref: 64] [Cited by in F6Publishing: 40] [Article Influence: 5.8] [Reference Citation Analysis]
108 Micheli F, Antolini M, Di Fabio R, Pellacani A, Pozzan A. 2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: A new class of selective orexin 2 antagonists. Bioorganic & Medicinal Chemistry Letters 2010;20:6405-7. [DOI: 10.1016/j.bmcl.2010.09.090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
109 Viviani D, Haegler P, Jenck F, Steiner MA. Orexin neuropeptides contribute to the development and persistence of generalized avoidance behavior in the rat. Psychopharmacology (Berl) 2015;232:1383-93. [PMID: 25319964 DOI: 10.1007/s00213-014-3769-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
110 Coleman PJ, Renger JJ. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opin Ther Pat 2010;20:307-24. [PMID: 20180618 DOI: 10.1517/13543770903567085] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
111 Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 2012;37:1224-33. [PMID: 22237311 DOI: 10.1038/npp.2011.310] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
112 Svetnik V, Snyder ES, Tao P, Scammell TE, Roth T, Lines C, Herring WJ. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts. Sleep 2018;41. [DOI: 10.1093/sleep/zsx178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
113 Wang C, Wang Q, Ji B, Pan Y, Xu C, Cheng B, Bai B, Chen J. The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. Front Mol Neurosci 2018;11:220. [PMID: 30002617 DOI: 10.3389/fnmol.2018.00220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
114 Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013;36:325-36. [PMID: 23449602 DOI: 10.5665/sleep.2442] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Laue G, Ofner S, Briard E, Gee CE, Jacobson LH, Hoyer D. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci 2013;7:230. [PMID: 24376396 DOI: 10.3389/fnins.2013.00230] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
116 Nair SG, Adams-Deutsch T, Epstein DH, Shaham Y. The neuropharmacology of relapse to food seeking: methodology, main findings, and comparison with relapse to drug seeking.Prog Neurobiol. 2009;89:18-45. [PMID: 19497349 DOI: 10.1016/j.pneurobio.2009.05.003] [Cited by in Crossref: 83] [Cited by in F6Publishing: 87] [Article Influence: 6.4] [Reference Citation Analysis]
117 Nishihachijo M, Hirai Y, Kawano S, Nishiyama A, Minami H, Katayama T, Yasohara Y, Sato F, Kumagai H. Asymmetric synthesis of tetrahydroisoquinolines by enzymatic Pictet–Spengler reaction. Bioscience, Biotechnology, and Biochemistry 2014;78:701-7. [DOI: 10.1080/09168451.2014.890039] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
118 Mieda M, Sakurai T. Overview of orexin/hypocretin system. Orexin/Hypocretin System. Elsevier; 2012. pp. 5-14. [DOI: 10.1016/b978-0-444-59489-1.00002-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
119 Roth T, Roehrs T. Pharmacotherapy for Insomnia. Sleep Medicine Clinics 2010;5:529-39. [DOI: 10.1016/j.jsmc.2010.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
120 Stasi LP, Artusi R, Bovino C, Buzzi B, Canciani L, Caselli G, Colace F, Garofalo P, Giambuzzi S, Larger P, Letari O, Mandelli S, Perugini L, Pucci S, Salvi M, Toro P. Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists. Bioorg Med Chem Lett 2013;23:2653-8. [PMID: 23535328 DOI: 10.1016/j.bmcl.2013.02.093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
121 Kubin L. Neural Control of the Upper Airway: Respiratory and State-Dependent Mechanisms. Compr Physiol 2016;6:1801-50. [PMID: 27783860 DOI: 10.1002/cphy.c160002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
122 Steiner MA, Lecourt H, Jenck F. The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat. Int J Neuropsychopharmacol 2013;16:417-32. [PMID: 22436395 DOI: 10.1017/S1461145712000193] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
123 Yin J, Mobarec JC, Kolb P, Rosenbaum DM. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Nature 2015;519:247-50. [DOI: 10.1038/nature14035] [Cited by in Crossref: 140] [Cited by in F6Publishing: 123] [Article Influence: 17.5] [Reference Citation Analysis]
124 Carter ME, Schaich Borg J, de Lecea L. The brain hypocretins and their receptors: mediators of allostatic arousal. Curr Opin Pharmacol 2009;9:39-45. [PMID: 19185540 DOI: 10.1016/j.coph.2008.12.018] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 4.9] [Reference Citation Analysis]
125 Sifferlen T, Koberstein R, Cottreel E, Boller A, Weller T, Gatfield J, Brisbare-roch C, Jenck F, Boss C. Synthesis, structure–activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1. Bioorganic & Medicinal Chemistry Letters 2013;23:2212-6. [DOI: 10.1016/j.bmcl.2013.01.088] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
126 Raizen DM, Wu MN. Genome-wide association studies of sleep disorders. Chest 2011;139:446-52. [PMID: 21285061 DOI: 10.1378/chest.10-1313] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
127 Gehrman P, Sengupta A, Harders E, Ubeydullah E, Pack AI, Weljie A. Altered diurnal states in insomnia reflect peripheral hyperarousal and metabolic desynchrony: a preliminary study. Sleep 2018;41. [PMID: 29522222 DOI: 10.1093/sleep/zsy043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
128 Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, Snyder E, Snavely D, Michelson D, Roth T, Herring WJ. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia. Int J Neuropsychopharmacol 2016;19:pyw022. [PMID: 26979830 DOI: 10.1093/ijnp/pyw022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
129 Janto K, Prichard JR, Pusalavidyasagar S. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics. J Clin Sleep Med 2018;14:1399-408. [PMID: 30092886 DOI: 10.5664/jcsm.7282] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
130 Kitajima S, Iwata Y, Furuichi K, Sagara A, Shinozaki Y, Toyama T, Sakai N, Shimizu M, Sakurai T, Kaneko S, Wada T. Messenger RNA expression profile of sleep-related genes in peripheral blood cells in patients with chronic kidney disease. Clin Exp Nephrol 2016;20:218-25. [DOI: 10.1007/s10157-015-1150-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
131 Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, Fraser I, Lord B, Shoblock J, Welty N, Chaplan SR, Aguilar Z, Halter R, Ndifor A, Koudriakova T, Rizzolio M, Letavic M, Carruthers NI, Lovenberg T, Dugovic C. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J Pharmacol Exp Ther 2015;354:471-82. [PMID: 26177655 DOI: 10.1124/jpet.115.225466] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
132 Sheean ME, Stoyanova-beninska V, Capovilla G, Duarte D, Hofer MP, Hoffmann M, Magrelli A, Mariz S, Tsigkos S, Shaili E, Polsinelli B, Ricciardi M, Bonelli M, Balabanov P, Larsson K, Sepodes B. Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions. Drug Discovery Today 2018;23:26-48. [DOI: 10.1016/j.drudis.2017.09.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
133 Zisapel N. Drugs for insomnia. Expert Opin Emerg Drugs 2012;17:299-317. [PMID: 22681198 DOI: 10.1517/14728214.2012.690735] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
134 Watson CJ, Baghdoyan HA, Lydic R. Neuropharmacology of Sleep and Wakefulness. Sleep Med Clin 2010;5:513-28. [PMID: 21278831 DOI: 10.1016/j.jsmc.2010.08.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
135 Biernacki K, Daśko M, Ciupak O, Kubiński K, Rachon J, Demkowicz S. Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery. Pharmaceuticals (Basel) 2020;13:E111. [PMID: 32485996 DOI: 10.3390/ph13060111] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
136 Wafford KA, Ebert B. Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nat Rev Drug Discov 2008;7:530-40. [PMID: 18511929 DOI: 10.1038/nrd2464] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 5.1] [Reference Citation Analysis]
137 Cao M, Guilleminault C. Hypocretin and its emerging role as a target for treatment of sleep disorders. Curr Neurol Neurosci Rep 2011;11:227-34. [PMID: 21170610 DOI: 10.1007/s11910-010-0172-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
138 Ajani OO, Familoni OB, Wu F, Echeme JO, Sujiang Z. Room temperature synthesis and antibacterial activity of new sulfonamides containing n,n-diethyl-substituted amido moieties. Int J Med Chem 2012;2012:367815. [PMID: 25374686 DOI: 10.1155/2012/367815] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
139 Vringer M, Kornum BR. Emerging therapeutic targets for narcolepsy. Expert Opin Ther Targets 2021;:1-14. [PMID: 34402358 DOI: 10.1080/14728222.2021.1969361] [Reference Citation Analysis]
140 Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 2013;8:898-903. [PMID: 23589487 DOI: 10.1002/cmdc.201300003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
141 Boof M, Alatrach A, Ufer M, Dingemanse J. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. Eur J Clin Pharmacol 2019;75:195-205. [DOI: 10.1007/s00228-018-2559-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
142 Guerrini R, Salvadori S, Rizzi A, Regoli D, Calo' G. Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev 2010;30:751-77. [PMID: 19824051 DOI: 10.1002/med.20180] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 6.6] [Reference Citation Analysis]
143 Srinivasan S, Simms JA, Nielsen CK, Lieske SP, Bito-Onon JJ, Yi H, Hopf FW, Bonci A, Bartlett SE. The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. PLoS One 2012;7:e44726. [PMID: 23028593 DOI: 10.1371/journal.pone.0044726] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
144 Kodadek T, Cai D. Chemistry and biology of orexin signaling. Mol Biosyst 2010;6:1366-75. [PMID: 20532299 DOI: 10.1039/c003468a] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
145 Hoyer D, Dürst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, Behnke D, Cotesta S, Laue G, Ofner S, Legangneux E, Gee CE. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci 2013;7:235. [PMID: 24368893 DOI: 10.3389/fnins.2013.00235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
146 Mavanji V, Teske JA, Billington CJ, Kotz CM. Elevated sleep quality and orexin receptor mRNA in obesity-resistant rats. Int J Obes (Lond) 2010;34:1576-88. [PMID: 20498657 DOI: 10.1038/ijo.2010.93] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
147 Kuduk SD, Winrow CJ, Coleman PJ. Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders. Elsevier; 2013. pp. 73-87. [DOI: 10.1016/b978-0-12-417150-3.00006-5] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
148 Sullivan SS. Insomnia pharmacology. Med Clin North Am 2010;94:563-80. [PMID: 20451033 DOI: 10.1016/j.mcna.2010.02.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
149 Pizza F, Barateau L, Dauvilliers Y, Plazzi G. The orexin story, sleep and sleep disturbances. J Sleep Res 2022;:e13665. [PMID: 35698789 DOI: 10.1111/jsr.13665] [Reference Citation Analysis]
150 Miller RA, Winrow CJ, Spellman DS, Song Q, Reiss DR, Conway JP, Taylor RR, Coleman PJ, Hendrickson RC, Renger JJ. Quantitative proteomics in laser capture microdissected sleep nuclei from rat brain. J Neurogenet 2014;28:136-45. [PMID: 24579665 DOI: 10.3109/01677063.2014.883389] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
151 Tripolitsiotis NP, Thomaidi M, Neochoritis CG. The Ugi Three‐Component Reaction; a Valuable Tool in Modern Organic Synthesis. Eur J Org Chem 2020;2020:6525-54. [DOI: 10.1002/ejoc.202001157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
152 DeMartinis NA, Kamath J, Winokur A. New approaches for the treatment of sleep disorders. Adv Pharmacol 2009;57:187-235. [PMID: 20230762 DOI: 10.1016/S1054-3589(08)57005-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
153 Rodgers RJ, Wright FL, Snow NF, Taylor LJ. Orexin-1 receptor antagonism fails to reduce anxiety-like behaviour in either plus-maze-naïve or plus-maze-experienced mice. Behav Brain Res 2013;243:213-9. [PMID: 23333844 DOI: 10.1016/j.bbr.2012.12.064] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
154 Doghramji PP. Integrating Modern Concepts of Insomnia and its Contemporary Treatment into Primary Care. Postgraduate Medicine 2015;126:82-101. [DOI: 10.3810/pgm.2014.09.2802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
155 Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med 2015;109:416-26. [PMID: 25661282 DOI: 10.1016/j.rmed.2014.12.010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
156 Yoshida Y, Naoe Y, Terauchi T, Ozaki F, Doko T, Takemura A, Tanaka T, Sorimachi K, Beuckmann CT, Suzuki M, Ueno T, Ozaki S, Yonaga M. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist. J Med Chem 2015;58:4648-64. [PMID: 25953512 DOI: 10.1021/acs.jmedchem.5b00217] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
157 Boss C, Roch C. Recent trends in orexin research—2010 to 2015. Bioorganic & Medicinal Chemistry Letters 2015;25:2875-87. [DOI: 10.1016/j.bmcl.2015.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
158 Corrigall WA. Hypocretin mechanisms in nicotine addiction: evidence and speculation. Psychopharmacology (Berl) 2009;206:23-37. [PMID: 19529922 DOI: 10.1007/s00213-009-1588-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
159 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
160 Hoch M, Hoever P, Alessi F, Theodor R, Dingemanse J. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects. Eur J Clin Pharmacol 2013;69:523-32. [PMID: 22990330 DOI: 10.1007/s00228-012-1403-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
161 Ghanemi A, Hu X. Targeting the orexinergic system: Mainly but not only for sleep-wakefulness therapies. Alexandria Journal of Medicine 2015;51:279-86. [DOI: 10.1016/j.ajme.2014.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
162 Beuckmann CT, Ueno T, Nakagawa M, Suzuki M, Akasofu S. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep 2019;42:zsz076. [PMID: 30923834 DOI: 10.1093/sleep/zsz076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
163 Moorman DE. The hypocretin/orexin system as a target for excessive motivation in alcohol use disorders. Psychopharmacology (Berl) 2018;235:1663-80. [PMID: 29508004 DOI: 10.1007/s00213-018-4871-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
164 Watson CJ, Baghdoyan HA, Lydic R. Neuropharmacology of Sleep and Wakefulness: 2012 Update. Sleep Med Clin 2012;7:469-86. [PMID: 23162386 DOI: 10.1016/j.jsmc.2012.06.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
165 López M, Tena-Sempere M, Diéguez C. Cross-talk between orexins (hypocretins) and the neuroendocrine axes (hypothalamic-pituitary axes). Front Neuroendocrinol 2010;31:113-27. [PMID: 19654017 DOI: 10.1016/j.yfrne.2009.07.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
166 Watanabe H, Idoko Y, Iikuni S, Ide T, Shimizu Y, Nakamoto Y, Ono M. Synthesis and biological evaluation of novel 18F-labeled phenylbenzofuran-2-carboxamide derivative for detection of orexin 1 receptor in the brain. Bioorg Med Chem Lett 2021;43:128098. [PMID: 33984472 DOI: 10.1016/j.bmcl.2021.128098] [Reference Citation Analysis]
167 Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D, Antolini M, Martinelli P, Cesari N, Montanari D, Tessari M, Corsi M, Bifone A. Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One 2011;6:e16406. [PMID: 21307957 DOI: 10.1371/journal.pone.0016406] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
168 Etori K, Saito YC, Tsujino N, Sakurai T. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice. Front Neurosci 2014;8:8. [PMID: 24550770 DOI: 10.3389/fnins.2014.00008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
169 Gamble MC, Katsuki F, McCoy JG, Strecker RE, McKenna JT. The Dual Orexin Receptor Antagonist DORA-22 Improves Mild Stress-induced Sleep Disruption During the Natural Sleep Phase of Nocturnal Rats. Neuroscience 2021;463:30-44. [PMID: 33737028 DOI: 10.1016/j.neuroscience.2021.03.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
170 Beig MI, Dampney BW, Carrive P. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Neuropharmacology 2015;89:146-56. [PMID: 25239810 DOI: 10.1016/j.neuropharm.2014.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
171 Tannenbaum PL, Tye SJ, Stevens J, Gotter AL, Fox SV, Savitz AT, Coleman PJ, Uslaner JM, Kuduk SD, Hargreaves R, Winrow CJ, Renger JJ. Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys. Sleep 2016;39:603-12. [PMID: 26943466 DOI: 10.5665/sleep.5536] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
172 Riemann D, Spiegelhalder K, Feige B, Voderholzer U, Berger M, Perlis M, Nissen C. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev 2010;14:19-31. [PMID: 19481481 DOI: 10.1016/j.smrv.2009.04.002] [Cited by in Crossref: 775] [Cited by in F6Publishing: 668] [Article Influence: 59.6] [Reference Citation Analysis]
173 Li SB, Jones JR, de Lecea L. Hypocretins, Neural Systems, Physiology, and Psychiatric Disorders. Curr Psychiatry Rep 2016;18:7. [PMID: 26733323 DOI: 10.1007/s11920-015-0639-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
174 Reddy NSS, Reddy BS. Stereoselective total synthesis of almorexant. Tetrahedron Letters 2014;55:3157-9. [DOI: 10.1016/j.tetlet.2014.03.130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
175 Pigeon WR, Bishop TM, Marcus JA. Advances in the management of insomnia. F1000Prime Rep 2014;6:48. [PMID: 24991425 DOI: 10.12703/P6-48] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
176 Behnke D, Cotesta S, Hintermann S, Fendt M, Gee CE, Jacobson LH, Laue G, Meyer A, Wagner T, Badiger S, Chaudhari V, Chebrolu M, Pandit C, Hoyer D, Betschart C. Discovery of 1 H -pyrazolo[3,4- b ]pyridines as potent dual orexin receptor antagonists (DORAs). Bioorganic & Medicinal Chemistry Letters 2015;25:5555-60. [DOI: 10.1016/j.bmcl.2015.10.055] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
177 Jenck F, Brisbare-roch C, Scherz M, Flores S, Koberstein R, Nayler O, Dingemanse J, Clozel M. Reply to 'Promotion of sleep by targeting the orexin system in rats, dogs and humans'. Nat Med 2007;13:526-526. [DOI: 10.1038/nm0507-526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
178 Firouzabadi N, Navabzadeh N, Moghimi-Sarani E, Haghnegahdar M. Orexin/Hypocretin Type 2 Receptor (HCRTR2) Gene as a Candidate Gene in Sertraline-Associated Insomnia in Depressed Patients. Neuropsychiatr Dis Treat 2020;16:1121-8. [PMID: 32440126 DOI: 10.2147/NDT.S250141] [Reference Citation Analysis]
179 Black SW, Schwartz MD, Chen TM, Hoener MC, Kilduff TS. Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics. Biol Psychiatry 2017;82:623-33. [PMID: 27919403 DOI: 10.1016/j.biopsych.2016.10.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
180 Bai P, Bai S, Placzek MS, Lu X, Fiedler SA, Ntaganda B, Wey HY, Wang C. A New Positron Emission Tomography Probe for Orexin Receptors Neuroimaging. Molecules 2020;25:E1018. [PMID: 32106419 DOI: 10.3390/molecules25051018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
181 Rosenwasser AM. Functional neuroanatomy of sleep and circadian rhythms. Brain Res Rev 2009;61:281-306. [PMID: 19695288 DOI: 10.1016/j.brainresrev.2009.08.001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
182 Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 2014;37:1609-19. [PMID: 25197807 DOI: 10.5665/sleep.4068] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
183 Thomasy HE, Opp MR. Hypocretin Mediates Sleep and Wake Disturbances in a Mouse Model of Traumatic Brain Injury. J Neurotrauma 2019;36:802-14. [PMID: 30136622 DOI: 10.1089/neu.2018.5810] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
184 Nattie E, Li A. Central chemoreceptors: locations and functions. Compr Physiol 2012;2:221-54. [PMID: 23728974 DOI: 10.1002/cphy.c100083] [Cited by in Crossref: 36] [Cited by in F6Publishing: 72] [Article Influence: 4.0] [Reference Citation Analysis]
185 Wei W, Motoike T, Krzeszinski JY, Jin Z, Xie XJ, Dechow PC, Yanagisawa M, Wan Y. Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action. Cell Metab 2014;19:927-40. [PMID: 24794976 DOI: 10.1016/j.cmet.2014.03.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
186 Brotschi C, Roch C, Gatfield J, Treiber A, Williams JT, Sifferlen T, Heidmann B, Jenck F, Bolli MH, Boss C. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep‐Promoting Properties in Rats. ChemMedChem 2019;14:1257-70. [DOI: 10.1002/cmdc.201900242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
187 Heidmann B, Gatfield J, Roch C, Treiber A, Tortoioli S, Brotschi C, Williams JT, Bolli MH, Abele S, Sifferlen T, Jenck F, Boss C. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach. ChemMedChem 2016;11:2132-46. [DOI: 10.1002/cmdc.201600175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
188 Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes MM, Schober DA, Rorick-Kehn LM. LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Front Neurosci 2014;8:5. [PMID: 24478625 DOI: 10.3389/fnins.2014.00005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
189 Dong YJ, Jiang NH, Zhan LH, Teng X, Fang X, Lin MQ, Xie ZY, Luo R, Li LZ, Li B, Zhang BB, Lv GY, Chen SH. Soporific effect of modified Suanzaoren Decoction on mice models of insomnia by regulating Orexin-A and HPA axis homeostasis. Biomed Pharmacother 2021;143:112141. [PMID: 34509822 DOI: 10.1016/j.biopha.2021.112141] [Reference Citation Analysis]
190 Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang X, Sutton SW, Bonaventure P, Yun S, Li X, Lord B, Dvorak CA, Carruthers NI, Lovenberg TW. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009;330:142-51. [PMID: 19363060 DOI: 10.1124/jpet.109.152009] [Cited by in Crossref: 150] [Cited by in F6Publishing: 154] [Article Influence: 11.5] [Reference Citation Analysis]
191 Uslaner JM, Renger JJ, Coleman PJ, Winrow CJ. A New Class of Hypnotic Compounds for the Treatment of Insomnia: The Dual Orexin Receptor Antagonists. In: Sakurai T, Pandi-perumal S, Monti JM, editors. Orexin and Sleep. Cham: Springer International Publishing; 2015. pp. 323-38. [DOI: 10.1007/978-3-319-23078-8_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
192 Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014;24:4884-90. [PMID: 25248679 DOI: 10.1016/j.bmcl.2014.08.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
193 Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Satlin A. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Sleep Med 2017;13:1289-99. [PMID: 29065953 DOI: 10.5664/jcsm.6800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
194 Sakurai T. Orexin deficiency and narcolepsy. Curr Opin Neurobiol 2013;23:760-6. [PMID: 23663890 DOI: 10.1016/j.conb.2013.04.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
195 Gaykema RP, Goehler LE. Lipopolysaccharide challenge-induced suppression of Fos in hypothalamic orexin neurons: their potential role in sickness behavior. Brain Behav Immun 2009;23:926-30. [PMID: 19328847 DOI: 10.1016/j.bbi.2009.03.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
196 Sinha MK, Khoury K, Herdtweck E, Dömling A. Tricycles by a new Ugi variation and Pictet-Spengler reaction in one pot. Chemistry 2013;19:8048-52. [PMID: 23649922 DOI: 10.1002/chem.201300962] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
197 Kram DE, Krasnow SM, Levasseur PR, Zhu X, Stork LC, Marks DL. Dexamethasone Chemotherapy Does Not Disrupt Orexin Signaling. PLoS One 2016;11:e0168731. [PMID: 27997622 DOI: 10.1371/journal.pone.0168731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
198 Schroeder AM, Colwell CS. How to fix a broken clock. Trends Pharmacol Sci 2013;34:605-19. [PMID: 24120229 DOI: 10.1016/j.tips.2013.09.002] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 9.9] [Reference Citation Analysis]
199 Mahoney CE, Mochizuki T, Scammell TE. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. Sleep 2020;43:zsz302. [PMID: 31830270 DOI: 10.1093/sleep/zsz302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
200 Kuduk SD, Skudlarek JW, Di Marco CN, Bruno JG, Pausch MA, O’brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ. Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant. Bioorganic & Medicinal Chemistry Letters 2014;24:1784-9. [DOI: 10.1016/j.bmcl.2014.02.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
201 Mezeiova E, Janockova J, Konecny J, Kobrlova T, Benkova M, Dolezal R, Prchal L, Karasova-Zdarova J, Soukup O, Korabecny J. From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia. Bioorg Chem 2020;103:104179. [PMID: 32891860 DOI: 10.1016/j.bioorg.2020.104179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Matzeu A, Martin-Fardon R. Targeting the Orexin System for Prescription Opioid Use Disorder. Brain Sci 2020;10:E226. [PMID: 32290110 DOI: 10.3390/brainsci10040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
203 Kim AK, Brown RM, Lawrence AJ. The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship. Front Behav Neurosci 2012;6:78. [PMID: 23189046 DOI: 10.3389/fnbeh.2012.00078] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
204 Carrive P. Orexin, orexin receptor antagonists and central cardiovascular control. Front Neurosci 2013;7:257. [PMID: 24415993 DOI: 10.3389/fnins.2013.00257] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
205 Beig MI, Horiuchi J, Dampney RA, Carrive P. Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus. Clin Exp Pharmacol Physiol 2015;42:1059-67. [DOI: 10.1111/1440-1681.12461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
206 [DOI: 10.1101/489005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
207 Coleman PJ, Schreier JD, Roecker AJ, Mercer SP, Mcgaughey GB, Cox CD, Hartman GD, Harrell CM, Reiss DR, Doran SM, Garson SL, Anderson WB, Tang C, Prueksaritanont T, Winrow CJ, Renger JJ. Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat. Bioorganic & Medicinal Chemistry Letters 2010;20:4201-5. [DOI: 10.1016/j.bmcl.2010.05.047] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
208 Buysse DJ. Clinical Pharmacology of Other Drugs Used as Hypnotics. Principles and Practice of Sleep Medicine. Elsevier; 2011. pp. 492-509. [DOI: 10.1016/b978-1-4160-6645-3.00043-8] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
209 Tsunematsu T, Tabuchi S, Tanaka KF, Boyden ES, Tominaga M, Yamanaka A. Long-lasting silencing of orexin/hypocretin neurons using archaerhodopsin induces slow-wave sleep in mice. Behav Brain Res 2013;255:64-74. [PMID: 23707248 DOI: 10.1016/j.bbr.2013.05.021] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 7.9] [Reference Citation Analysis]
210 Paterson LM, Nutt DJ, Wilson SJ. Sleep and its disorders in translational medicine. J Psychopharmacol 2011;25:1226-34. [PMID: 21490119 DOI: 10.1177/0269881111400643] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
211 Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, Dingemanse J. Absolute Oral Bioavailability of Almorexant, a Dual Orexin Receptor Antagonist, in Healthy Human Subjects. Pharmacology 2012;89:53-7. [DOI: 10.1159/000335367] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
212 Teske JA, Billington CJ, Kotz CM. Hypocretin/orexin and energy expenditure. Acta Physiol (Oxf) 2010;198:303-12. [PMID: 20070282 DOI: 10.1111/j.1748-1716.2010.02075.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
213 Roch C, Bergamini G, Steiner MA, Clozel M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl) 2021;238:2693-708. [PMID: 34415378 DOI: 10.1007/s00213-021-05954-0] [Reference Citation Analysis]
214 Schwartz MD, Nguyen AT, Warrier DR, Palmerston JB, Thomas AM, Morairty SR, Neylan TC, Kilduff TS. Locus Coeruleus and Tuberomammillary Nuclei Ablations Attenuate Hypocretin/Orexin Antagonist-Mediated REM Sleep. eNeuro. 2016;3:pii: ENEURO.0018-16.2016. [PMID: 27022631 DOI: 10.1523/eneuro.0018-16.2016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
215 Nollet M, Gaillard P, Tanti A, Girault V, Belzung C, Leman S. Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology 2012;37:2210-21. [PMID: 22713907 DOI: 10.1038/npp.2012.70] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 9.1] [Reference Citation Analysis]
216 Mano Y, Ueno T, Hotta K. Establishment of a simultaneous assay for lemborexant, a novel dual orexin receptor antagonist, and its three metabolites, and its application to a clinical protein binding study. Journal of Pharmaceutical and Biomedical Analysis 2020;187:113359. [DOI: 10.1016/j.jpba.2020.113359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Raheem IT, Breslin MJ, Bruno J, Cabalu TD, Cooke A, Cox CD, Cui D, Garson S, Gotter AL, Fox SV, Harrell CM, Kuduk SD, Lemaire W, Prueksaritanont T, Renger JJ, Stump C, Tannenbaum PL, Williams PD, Winrow CJ, Coleman PJ. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. Bioorganic & Medicinal Chemistry Letters 2015;25:444-50. [DOI: 10.1016/j.bmcl.2014.12.056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
218 de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J. Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 2010;24:1619-29. [PMID: 19648220 DOI: 10.1177/0269881109106898] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
219 Cerri M, Del Vecchio F, Mastrotto M, Luppi M, Martelli D, Perez E, Tupone D, Zamboni G, Amici R. Enhanced slow-wave EEG activity and thermoregulatory impairment following the inhibition of the lateral hypothalamus in the rat. PLoS One 2014;9:e112849. [PMID: 25398141 DOI: 10.1371/journal.pone.0112849] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
220 López M, Lage R, Tung YC, Challis BG, Varela L, Virtue S, O'Rahilly S, Vidal-Puig A, Diéguez C, Coll AP. Orexin expression is regulated by alpha-melanocyte-stimulating hormone. J Neuroendocrinol 2007;19:703-7. [PMID: 17680885 DOI: 10.1111/j.1365-2826.2007.01577.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
221 Szabadi E. Selective targets for arousal-modifying drugs: implications for the treatment of sleep disorders. Drug Discovery Today 2014;19:701-8. [DOI: 10.1016/j.drudis.2014.01.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
222 Muehlan C, Boehler M, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. J Psychopharmacol 2020;34:326-35. [DOI: 10.1177/0269881119882854] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
223 Song J, Kim E, Kim CH, Song HT, Lee JE. The role of orexin in post-stroke inflammation, cognitive decline, and depression. Mol Brain 2015;8:16. [PMID: 25884812 DOI: 10.1186/s13041-015-0106-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
224 Boss C, Gatfield J, Brotschi C, Heidmann B, Sifferlen T, von Raumer M, Schmidt G, Williams JT, Treiber A, Roch C. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. ChemMedChem 2020;15:2286-305. [PMID: 32937014 DOI: 10.1002/cmdc.202000453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
225 Li A, Hindmarch CC, Nattie EE, Paton JF. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol 2013;591:4237-48. [PMID: 23671161 DOI: 10.1113/jphysiol.2013.256271] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 7.4] [Reference Citation Analysis]
226 Nixon JP, Mavanji V, Butterick TA, Billington CJ, Kotz CM, Teske JA. Sleep disorders, obesity, and aging: the role of orexin. Ageing Res Rev 2015;20:63-73. [PMID: 25462194 DOI: 10.1016/j.arr.2014.11.001] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 10.1] [Reference Citation Analysis]
227 Hoch M, Hoever P, Alessi F, Marjason J, Dingemanse J. Pharmacokinetics and Tolerability of Almorexant in Japanese and Caucasian Healthy Male Subjects. Pharmacology 2011;88:121-6. [DOI: 10.1159/000330098] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
228 Alam MA, Mallick BN. Glutamic acid stimulation of the perifornical-lateral hypothalamic area promotes arousal and inhibits non-REM/REM sleep. Neurosci Lett. 2008;439:281-286. [PMID: 18534750 DOI: 10.1016/j.neulet.2008.05.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
229 Mercer SP, Roecker AJ, Garson S, Reiss DR, Meacham Harrell C, Murphy KL, Bruno JG, Bednar RA, Lemaire W, Cui D, Cabalu TD, Tang C, Prueksaritanont T, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs). Bioorg Med Chem Lett 2013;23:6620-4. [PMID: 24215892 DOI: 10.1016/j.bmcl.2013.10.045] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
230 Adamantidis A, Carter MC, de Lecea L. Optogenetic deconstruction of sleep-wake circuitry in the brain. Front Mol Neurosci 2010;2:31. [PMID: 20126433 DOI: 10.3389/neuro.02.031.2009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
231 Gentile TA, Simmons SJ, Watson MN, Connelly KL, Brailoiu E, Zhang Y, Muschamp JW. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine. Neuropsychopharmacology 2018;43:1001-9. [PMID: 28741623 DOI: 10.1038/npp.2017.158] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
232 Coleman PJ, Schreier JD, McGaughey GB, Bogusky MJ, Cox CD, Hartman GD, Ball RG, Harrell CM, Reiss DR, Prueksaritanont T, Winrow CJ, Renger JJ. Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists. Bioorg Med Chem Lett 2010;20:2311-5. [PMID: 20207138 DOI: 10.1016/j.bmcl.2010.01.138] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
233 Christopher JA. Orexin receptor antagonists. Pharm Pat Anal 2012;1:329-46. [PMID: 24236845 DOI: 10.4155/ppa.12.27] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
234 Muehlan C, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. European Neuropsychopharmacology 2019;29:847-57. [DOI: 10.1016/j.euroneuro.2019.05.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
235 Fujimoto T, Kunitomo J, Tomata Y, Nishiyama K, Nakashima M, Hirozane M, Yoshikubo S, Hirai K, Marui S. Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists. Bioorg Med Chem Lett 2011;21:6414-6. [PMID: 21917455 DOI: 10.1016/j.bmcl.2011.08.093] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
236 Loiseau C, Casciato A, Barka B, Cayetanot F, Bodineau L. Orexin Neurons Contribute to Central Modulation of Respiratory Drive by Progestins on ex vivo Newborn Rodent Preparations. Front Physiol 2019;10:1200. [PMID: 31611806 DOI: 10.3389/fphys.2019.01200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
237 Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ, Mcgaughey GB, Bednar RA, Lemaire W, Doran SM, Fox SV, Garson SL, Gotter AL, Harrell CM, Reiss DR, Cabalu TD, Cui D, Prueksaritanont T, Stevens J, Tannenbaum PL, Ball RG, Stellabott J, Young SD, Hartman GD, Winrow CJ, Renger JJ. Discovery of [(2 R ,5 R )-5-{[(5-Fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): A Dual Orexin Receptor Antagonist with Potent Sleep-Promoting Properties. ChemMedChem 2012;7:415-24. [DOI: 10.1002/cmdc.201200025] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 8.2] [Reference Citation Analysis]
238 Scammell TE, Saper CB. Orexins: looking forward to sleep, back at addiction. Nat Med 2007;13:126-8. [PMID: 17290266 DOI: 10.1038/nm0207-126] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
239 Flores-Ramirez FJ, Matzeu A, Sánchez-Marín L, Martin-Fardon R. Blockade of corticotropin-releasing factor-1 receptors in the infralimbic cortex prevents stress-induced reinstatement of alcohol seeking in male Wistar rats: Evidence of interaction between CRF1 and orexin receptor signaling. Neuropharmacology 2022;:109046. [PMID: 35341789 DOI: 10.1016/j.neuropharm.2022.109046] [Reference Citation Analysis]
240 Schwartz MD, Kilduff TS. The Neurobiology of Sleep and Wakefulness. Psychiatr Clin North Am 2015;38:615-44. [PMID: 26600100 DOI: 10.1016/j.psc.2015.07.002] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 11.9] [Reference Citation Analysis]
241 Li SB, Nevárez N, Giardino WJ, de Lecea L. Optical probing of orexin/hypocretin receptor antagonists. Sleep 2018;41. [PMID: 30060151 DOI: 10.1093/sleep/zsy141] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
242 Steiner MA, Sciarretta C, Brisbare-Roch C, Strasser DS, Studer R, Jenck F. Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat. Psychoneuroendocrinology 2013;38:560-71. [PMID: 22917622 DOI: 10.1016/j.psyneuen.2012.07.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
243 Alexandre C, Andermann ML, Scammell TE. Control of arousal by the orexin neurons. Curr Opin Neurobiol 2013;23:752-9. [PMID: 23683477 DOI: 10.1016/j.conb.2013.04.008] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 8.0] [Reference Citation Analysis]
244 Uemura N, McCrea J, Sun H, Donikyan M, Zammit G, Liu R, Louridas B, Marsilio S, Lines C, Troyer MD, Wagner J. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects. J Clin Pharmacol 2015;55:1093-100. [PMID: 25903940 DOI: 10.1002/jcph.523] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
245 Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013;36:325-36. [PMID: 23449602 DOI: 10.5665/sleep.2442] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
246 Pałasz A, Lapray D, Peyron C, Rojczyk-Gołębiewska E, Skowronek R, Markowski G, Czajkowska B, Krzystanek M, Wiaderkiewicz R. Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders. Int J Neuropsychopharmacol 2014;17:157-68. [PMID: 23702225 DOI: 10.1017/S1461145713000552] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
247 Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F. Biochemical and Electrophysiological Characterization of Almorexant, a Dual Orexin 1 Receptor (OX 1 )/Orexin 2 Receptor (OX 2 ) Antagonist: Comparison with Selective OX 1 and OX 2 Antagonists. Mol Pharmacol 2009;76:618-31. [DOI: 10.1124/mol.109.055152] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 4.2] [Reference Citation Analysis]
248 Teske JA, Mavanji V. Energy expenditure: role of orexin. Vitam Horm 2012;89:91-109. [PMID: 22640610 DOI: 10.1016/B978-0-12-394623-2.00006-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
249 Sullivan SS, Guilleminault C. Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs 2009;14:411-22. [PMID: 19708818 DOI: 10.1517/14728210903171948] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
250 Kelz MB, Sun Y, Chen J, Cheng Meng Q, Moore JT, Veasey SC, Dixon S, Thornton M, Funato H, Yanagisawa M. An essential role for orexins in emergence from general anesthesia. Proc Natl Acad Sci USA. 2008;105:1309-1314. [PMID: 18195361 DOI: 10.1073/pnas.0707146105] [Cited by in Crossref: 205] [Cited by in F6Publishing: 186] [Article Influence: 14.6] [Reference Citation Analysis]
251 Sifferlen T, Boller A, Chardonneau A, Cottreel E, Gatfield J, Treiber A, Roch C, Jenck F, Aissaoui H, Williams JT, Brotschi C, Heidmann B, Siegrist R, Boss C. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2. Bioorganic & Medicinal Chemistry Letters 2015;25:1884-91. [DOI: 10.1016/j.bmcl.2015.03.035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
252 Barateau L, Lopez R, Chenini S, Rassu A, Scholz S, Lotierzo M, Cristol J, Jaussent I, Dauvilliers Y. Association of CSF orexin-A levels and nocturnal sleep stability in patients with hypersomnolence. Neurology 2020;95:e2900-11. [DOI: 10.1212/wnl.0000000000010743] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
253 de Lecea L. A decade of hypocretins: past, present and future of the neurobiology of arousal. Acta Physiol (Oxf) 2010;198:203-8. [PMID: 19473132 DOI: 10.1111/j.1748-1716.2009.02004.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
254 Bastianini S, Silvani A, Berteotti C, Elghozi JL, Franzini C, Lenzi P, Lo Martire V, Zoccoli G. Sleep related changes in blood pressure in hypocretin-deficient narcoleptic mice. Sleep 2011;34:213-8. [PMID: 21286242 DOI: 10.1093/sleep/34.2.213] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]
255 Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27:14239-47. [PMID: 18160631 DOI: 10.1523/JNEUROSCI.3878-07.2007] [Cited by in Crossref: 186] [Cited by in F6Publishing: 78] [Article Influence: 13.3] [Reference Citation Analysis]
256 Nollet M, Gaillard P, Minier F, Tanti A, Belzung C, Leman S. Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology 2011;61:336-46. [PMID: 21530551 DOI: 10.1016/j.neuropharm.2011.04.022] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
257 Hoever P, Dorffner G, Beneš H, Penzel T, Danker-Hopfe H, Barbanoj MJ, Pillar G, Saletu B, Polo O, Kunz D, Zeitlhofer J, Berg S, Partinen M, Bassetti CL, Högl B, Ebrahim IO, Holsboer-Trachsler E, Bengtsson H, Peker Y, Hemmeter UM, Chiossi E, Hajak G, Dingemanse J. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 2012;91:975-85. [PMID: 22549286 DOI: 10.1038/clpt.2011.370] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 9.3] [Reference Citation Analysis]
258 Tran D, Bonaventure P, Hack M, Mirzadegan T, Dvorak C, Letavic M, Carruthers N, Lovenberg T, Sutton SW. Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. European Journal of Pharmacology 2011;667:120-8. [DOI: 10.1016/j.ejphar.2011.05.074] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
259 Coleman P, de Lecea L, Gotter A, Hagan J, Hoyer D, Kilduff T, Kukkonen JP, Porter R, Renger J, Siegel JM, Sutcliffe G, Upton N, Winrow CJ. Orexin receptors in GtoPdb v.2021.3. IUPHAR BPS Guide Pharm CITE 2021;2021. [PMID: 34927075 DOI: 10.2218/gtopdb/f51/2021.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Shakeri-Nejad K, Hoch M, Hoever P, Dingemanse J. Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist. Eur J Pharm Sci 2013;49:836-44. [PMID: 23770377 DOI: 10.1016/j.ejps.2013.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
261 Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 2007;8:171-81. [DOI: 10.1038/nrn2092] [Cited by in Crossref: 763] [Cited by in F6Publishing: 716] [Article Influence: 50.9] [Reference Citation Analysis]
262 Li SB, Giardino WJ, de Lecea L. Hypocretins and Arousal. Curr Top Behav Neurosci 2017;33:93-104. [PMID: 28012091 DOI: 10.1007/7854_2016_58] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
263 Li A, Roy SH, Nattie EE. An augmented CO2 chemoreflex and overactive orexin system are linked with hypertension in young and adult spontaneously hypertensive rats. J Physiol 2016;594:4967-80. [PMID: 27061304 DOI: 10.1113/JP272199] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
264 Brown JA, Woodworth HL, Leinninger GM. To ingest or rest? Specialized roles of lateral hypothalamic area neurons in coordinating energy balance. Front Syst Neurosci 2015;9:9. [PMID: 25741247 DOI: 10.3389/fnsys.2015.00009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
265 Nattie E, Li A. Central chemoreceptors: locations and functions. Compr Physiol 2012;2:221-54. [PMID: 23728974 DOI: 10.1002/cphy.c100083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
266 Demeestere D, Libert C, Vandenbroucke RE. Therapeutic implications of the choroid plexus-cerebrospinal fluid interface in neuropsychiatric disorders. Brain Behav Immun 2015;50:1-13. [PMID: 26116435 DOI: 10.1016/j.bbi.2015.06.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
267 Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JI, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowlby MR, Kuduk SD, Coleman PJ, Hargreaves R, Winrow CJ, Renger JJ. Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology 2013;38:2401-8. [PMID: 23722242 DOI: 10.1038/npp.2013.139] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
268 Bryant AJ, Ebrahimi E, Nguyen A, Wolff CA, Gumz ML, Liu AC, Esser KA. A Wrinkle in Time: Circadian biology in pulmonary vascular health and disease. Am J Physiol Lung Cell Mol Physiol 2021. [PMID: 34850650 DOI: 10.1152/ajplung.00037.2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Zeitzer JM, Buckmaster CL, Lyons DM, Mignot E. Increasing length of wakefulness and modulation of hypocretin-1 in the wake-consolidated squirrel monkey. Am J Physiol Regul Integr Comp Physiol 2007;293:R1736-42. [PMID: 17686881 DOI: 10.1152/ajpregu.00460.2007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
270 Dias MB, Li A, Nattie E. The orexin receptor 1 (OX1R) in the rostral medullary raphe contributes to the hypercapnic chemoreflex in wakefulness, during the active period of the diurnal cycle. Respir Physiol Neurobiol 2010;170:96-102. [PMID: 19995618 DOI: 10.1016/j.resp.2009.12.002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
271 Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013;36:259-67. [PMID: 23372274 DOI: 10.5665/sleep.2386] [Cited by in Crossref: 11] [Cited by in F6Publishing: 48] [Article Influence: 1.2] [Reference Citation Analysis]
272 de Haas S, Dingemanse J, Hoever P, Cohen A, van Gerven J. Pseudohallucinations after zolpidem intake: a case report. J Clin Psychopharmacol 2007;27:728-30. [PMID: 18004155 DOI: 10.1097/JCP.0b013e31815a5806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
273 Vicente MC, Dias MB, Fonseca EM, Bícego KC, Gargaglioni LH. Orexinergic system in the locus coeruleus modulates the CO2 ventilatory response. Pflugers Arch - Eur J Physiol 2016;468:763-74. [DOI: 10.1007/s00424-016-1793-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
274 Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. [PMID: 23034387 DOI: 10.1152/ajpcell.00227.2012] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
275 LeSage MG, Perry JL, Kotz CM, Shelley D, Corrigall WA. Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA. Psychopharmacology (Berl) 2010;209:203-12. [PMID: 20177882 DOI: 10.1007/s00213-010-1792-0] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 5.3] [Reference Citation Analysis]
276 Sakurai T. The role of orexin in motivated behaviours. Nat Rev Neurosci 2014;15:719-31. [DOI: 10.1038/nrn3837] [Cited by in Crossref: 244] [Cited by in F6Publishing: 221] [Article Influence: 30.5] [Reference Citation Analysis]
277 Walker LC, Lawrence AJ. The Role of Orexins/Hypocretins in Alcohol Use and Abuse. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 221-46. [DOI: 10.1007/7854_2016_55] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
278 Ohno K, Sakurai T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol 2008;29:70-87. [PMID: 17910982 DOI: 10.1016/j.yfrne.2007.08.001] [Cited by in Crossref: 178] [Cited by in F6Publishing: 162] [Article Influence: 11.9] [Reference Citation Analysis]
279 Yakupov EZ, Artemieva DV, Troshina YV. [Multimodality of clinical effects of orexin]. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118:114-9. [PMID: 30698570 DOI: 10.17116/jnevro2018118121114] [Reference Citation Analysis]
280 Bland H, Li X, Mangin E, Yee KL, Lines C, Herring WJ, Gillespie G. Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning. J Clin Psychopharmacol 2021;41:414-20. [PMID: 34181362 DOI: 10.1097/JCP.0000000000001439] [Reference Citation Analysis]
281 Perez-Leighton CE, Billington CJ, Kotz CM. Orexin modulation of adipose tissue. Biochim Biophys Acta 2014;1842:440-5. [PMID: 23791983 DOI: 10.1016/j.bbadis.2013.06.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
282 Futamura A, Suzuki R, Tamura Y, Kawamoto H, Ohmichi M, Hino N, Tokumaru Y, Kirinuki S, Hiyoshi T, Aoki T, Kambe D, Nozawa D. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia. Bioorganic & Medicinal Chemistry 2020;28:115489. [DOI: 10.1016/j.bmc.2020.115489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
283 Wang C, Moseley CK, Carlin SM, Wilson CM, Neelamegam R, Hooker JM. Radiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 receptors. Bioorg Med Chem Lett 2013;23:3389-92. [PMID: 23601709 DOI: 10.1016/j.bmcl.2013.03.079] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
284 Mcdonald T, Liang HA, Sanoja R, Gotter AL, Kuduk SD, Coleman PJ, Smith KM, Winrow CJ, Renger JJ. Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain. Journal of Neurogenetics 2016;30:32-41. [DOI: 10.3109/01677063.2016.1171862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
285 Hulme C, Ayaz M, Martinez-ariza G, Medda F, Shaw A. Recent Advances in Multicomponent Reaction Chemistry. In: Czechtizky W, Hamley P, editors. Small Molecule Medicinal Chemistry. Hoboken: John Wiley & Sons, Inc; 2015. pp. 145-87. [DOI: 10.1002/9781118771723.ch6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
286 Yoshida Y, Terauchi T, Naoe Y, Kazuta Y, Ozaki F, Beuckmann CT, Nakagawa M, Suzuki M, Kushida I, Takenaka O, Ueno T, Yonaga M. Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists. Bioorg Med Chem 2014;22:6071-88. [PMID: 25267004 DOI: 10.1016/j.bmc.2014.08.034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
287 Prud'homme MJ, Lacroix MC, Badonnel K, Gougis S, Baly C, Salesse R, Caillol M. Nutritional status modulates behavioural and olfactory bulb Fos responses to isoamyl acetate or food odour in rats: roles of orexins and leptin. Neuroscience 2009;162:1287-98. [PMID: 19477242 DOI: 10.1016/j.neuroscience.2009.05.043] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
288 Bonnavion P, de Lecea L. Hypocretins in the Control of Sleep and Wakefulness. Curr Neurol Neurosci Rep 2010;10:174-9. [DOI: 10.1007/s11910-010-0101-y] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
289 Struyk A, Gargano C, Drexel M, Stoch SA, Svetnik V, Ma J, Mayleben D. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects. Eur Neuropsychopharmacol 2016;26:1649-56. [PMID: 27554636 DOI: 10.1016/j.euroneuro.2016.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
290 Dietrich H, Jenck F. Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology (Berl) 2010;212:145-54. [PMID: 20631993 DOI: 10.1007/s00213-010-1933-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
291 Szymusiak R, McGinty D. Hypothalamic regulation of sleep and arousal. Ann N Y Acad Sci 2008;1129:275-86. [PMID: 18591488 DOI: 10.1196/annals.1417.027] [Cited by in Crossref: 173] [Cited by in F6Publishing: 158] [Article Influence: 12.4] [Reference Citation Analysis]
292 Piccoli L, Micioni Di Bonaventura MV, Cifani C, Costantini VJ, Massagrande M, Montanari D, Martinelli P, Antolini M, Ciccocioppo R, Massi M, Merlo-Pich E, Di Fabio R, Corsi M. Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology 2012;37:1999-2011. [PMID: 22569505 DOI: 10.1038/npp.2012.48] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 8.6] [Reference Citation Analysis]
293 Roundtree HM, Simeone TA, Johnson C, Matthews SA, Samson KK, Simeone KA. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice. Sleep 2016;39:357-68. [PMID: 26446112 DOI: 10.5665/sleep.5444] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
294 Tafti M. Reply to 'Promotion of sleep by targeting the orexin system in rats, dogs and humans'. Nat Med 2007;13:525-6; author reply 526. [PMID: 17479088 DOI: 10.1038/nm0507-525] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
295 Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, Gomeni R, Alexander R. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol 2012;26:1058-70. [PMID: 21730017 DOI: 10.1177/0269881111408954] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
296 Stahl SM. Mechanism of action of suvorexant. CNS Spectr 2016;21:215-8. [DOI: 10.1017/s1092852916000225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
297 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
298 Wang C, Wilson CM, Moseley CK, Carlin SM, Hsu S, Arabasz G, Schroeder FA, Sander CY, Hooker JM. Evaluation of potential PET imaging probes for the orexin 2 receptors. Nucl Med Biol 2013;40:1000-5. [PMID: 23953751 DOI: 10.1016/j.nucmedbio.2013.07.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
299 Brown RM, Khoo SY, Lawrence AJ. Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats. International Journal of Neuropsychopharmacology 2013;16:2067-79. [DOI: 10.1017/s1461145713000333] [Cited by in Crossref: 66] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
300 Liu F, Majo VJ, Prabhakaran J, Castrillion J, Mann JJ, Martinez D, Kumar JD. Radiosynthesis of [11C]BBAC and [11C]BBPC as potential PET tracers for orexin2 receptors. Bioorganic & Medicinal Chemistry Letters 2012;22:2172-4. [DOI: 10.1016/j.bmcl.2012.01.114] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
301 Boof ML, Dingemanse J, Lederer K, Fietze I, Ufer M. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep 2021;44:zsaa275. [PMID: 33305817 DOI: 10.1093/sleep/zsaa275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
302 Gestreau C, Bévengut M, Dutschmann M. The dual role of the orexin/hypocretin system in modulating wakefulness and respiratory drive. Curr Opin Pulm Med 2008;14:512-8. [PMID: 18812827 DOI: 10.1097/MCP.0b013e32831311d3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
303 Plaza-Zabala A, Maldonado R, Berrendero F. The hypocretin/orexin system: implications for drug reward and relapse. Mol Neurobiol 2012;45:424-39. [PMID: 22430644 DOI: 10.1007/s12035-012-8255-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
304 Boss C, Roch C. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934). Expert Opin Ther Pat 2016;26:409-15. [PMID: 26593218 DOI: 10.1517/13543776.2016.1124087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
305 Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 2013;47:477-88. [DOI: 10.1016/j.npep.2013.10.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
306 Dingemanse J, Krause A. Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development. Eur J Pharm Sci 2017;109S:S53-8. [PMID: 28535992 DOI: 10.1016/j.ejps.2017.05.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
307 Steiner MA, Lecourt H, Strasser DS, Brisbare-Roch C, Jenck F. Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology 2011;36:848-56. [PMID: 21150905 DOI: 10.1038/npp.2010.224] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
308 Tannenbaum PL, Stevens J, Binns J, Savitz AT, Garson SL, Fox SV, Coleman P, Kuduk SD, Gotter AL, Marino M, Tye SJ, Uslaner JM, Winrow CJ, Renger JJ. Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Front Behav Neurosci 2014;8:182. [PMID: 24904334 DOI: 10.3389/fnbeh.2014.00182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
309 Carrive P, Kuwaki T. Orexin and Central Modulation of Cardiovascular and Respiratory Function. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 157-96. [DOI: 10.1007/7854_2016_46] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
310 Snyder E, Ma J, Svetnik V, Connor KM, Lines C, Michelson D, Herring WJ. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Med 2016;19:93-100. [PMID: 27198953 DOI: 10.1016/j.sleep.2015.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
311 Sifferlen T, Koberstein R, Cottreel E, Boller A, Weller T, Gatfield J, Brisbare-Roch C, Jenck F, Boss C. Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2. Bioorg Med Chem Lett 2013;23:3857-63. [PMID: 23719231 DOI: 10.1016/j.bmcl.2013.04.071] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
312 Nattie E, Li A. Central chemoreception in wakefulness and sleep: evidence for a distributed network and a role for orexin. J Appl Physiol (1985) 2010;108:1417-24. [PMID: 20133433 DOI: 10.1152/japplphysiol.01261.2009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
313 Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
314 Winrow CJ, Tanis KQ, Reiss DR, Rigby AM, Uslaner JM, Uebele VN, Doran SM, Fox SV, Garson SL, Gotter AL, Levine DM, Roecker AJ, Coleman PJ, Koblan KS, Renger JJ. Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology 2010;58:185-94. [DOI: 10.1016/j.neuropharm.2009.07.008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
315 Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia. Neuropharmacology 2012;62:978-87. [DOI: 10.1016/j.neuropharm.2011.10.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 91] [Article Influence: 9.1] [Reference Citation Analysis]
316 Neubauer DN. New and emerging pharmacotherapeutic approaches for insomnia. International Review of Psychiatry 2014;26:214-24. [DOI: 10.3109/09540261.2014.888990] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
317 Berger B, Dingemanse J, Sabattini G, Delahaye S, Duthaler U, Muehlan C, Krähenbühl S. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clin Pharmacokinet 2021. [PMID: 34002356 DOI: 10.1007/s40262-021-01028-8] [Reference Citation Analysis]
318 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
319 Valko PO, Gavrilov YV, Yamamoto M, Reddy H, Haybaeck J, Mignot E, Baumann CR, Scammell TE. Increase of histaminergic tuberomammillary neurons in narcolepsy: Histaminergic Neurons. Ann Neurol 2013;74:794-804. [DOI: 10.1002/ana.24019] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 10.6] [Reference Citation Analysis]
320 Tharakan R, Kreimer S, Ubaida-mohien C, Lavoie J, Olexiouk V, Menschaert G, Ingolia NT, Cole RN, Ishizuka K, Sawa A, Nucifora LG. A methodology for discovering novel brain-relevant peptides: Combination of ribosome profiling and peptidomics. Neuroscience Research 2020;151:31-7. [DOI: 10.1016/j.neures.2019.02.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
321 Urstadt KR, Kally P, Zaidi SF, Stanley BG. Ipsilateral feeding-specific circuits between the nucleus accumbens shell and the lateral hypothalamus: regulation by glutamate and GABA receptor subtypes. Neuropharmacology 2013;67:176-82. [PMID: 23164617 DOI: 10.1016/j.neuropharm.2012.10.027] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
322 Tyree SM, de Lecea L. Optogenetic Investigation of Arousal Circuits. Int J Mol Sci 2017;18:E1773. [PMID: 28809797 DOI: 10.3390/ijms18081773] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
323 Suzuki H, Hibino H. The effect of lemborexant for insomnia disorder. SAGE Open Med 2021;9:20503121211039098. [PMID: 34422270 DOI: 10.1177/20503121211039098] [Reference Citation Analysis]
324 Yao L, Ramirez AD, Roecker AJ, Fox SV, Uslaner JM, Smith SM, Hodgson R, Coleman PJ, Renger JJ, Winrow CJ, Gotter AL. The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine. J Neurochem 2017;142:204-14. [PMID: 28444767 DOI: 10.1111/jnc.14055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
325 Nagase H, Yamamoto N, Yata M, Ohrui S, Okada T, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ishikawa Y, Ogawa Y, Hirayama S, Kuroda D, Watanabe Y, Gouda H, Yanagisawa M. Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies. J Med Chem 2017;60:1018-40. [DOI: 10.1021/acs.jmedchem.6b01418] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
326 Xu T, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular Signalling 2013;25:2413-23. [DOI: 10.1016/j.cellsig.2013.07.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
327 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
328 Li SB, de Lecea L. The hypocretin (orexin) system: from a neural circuitry perspective. Neuropharmacology 2020;167:107993. [PMID: 32135427 DOI: 10.1016/j.neuropharm.2020.107993] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
329 Liu AC, Lewis WG, Kay SA. Mammalian circadian signaling networks and therapeutic targets. Nat Chem Biol 2007;3:630-9. [PMID: 17876320 DOI: 10.1038/nchembio.2007.37] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 7.6] [Reference Citation Analysis]
330 van der Ark PD, Golor G, van Nueten L, Nandy P, de Boer P. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. J Psychopharmacol 2018;32:1330-40. [DOI: 10.1177/0269881118791521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
331 Di Fabio R, Pellacani A, Faedo S, Roth A, Piccoli L, Gerrard P, Porter RA, Johnson CN, Thewlis K, Donati D, Stasi L, Spada S, Stemp G, Nash D, Branch C, Kindon L, Massagrande M, Poffe A, Braggio S, Chiarparin E, Marchioro C, Ratti E, Corsi M. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorganic & Medicinal Chemistry Letters 2011;21:5562-7. [DOI: 10.1016/j.bmcl.2011.06.086] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
332 Kim SJ, Pilowsky PM, Farnham MM. Intrathecal Intermittent Orexin-A Causes Sympathetic Long-Term Facilitation and Sensitizes the Peripheral Chemoreceptor Response to Hypoxia in Rats. J Pharmacol Exp Ther 2016;358:492-501. [PMID: 27384072 DOI: 10.1124/jpet.116.234443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
333 Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem 2009;52:891-903. [PMID: 19199652 DOI: 10.1021/jm801296d] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
334 Mang GM, Dürst T, Bürki H, Imobersteg S, Abramowski D, Schuepbach E, Hoyer D, Fendt M, Gee CE. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 2012;35:1625-35. [PMID: 23204605 DOI: 10.5665/sleep.2232] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 6.1] [Reference Citation Analysis]
335 Mamelak M. Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. Prog Neurobiol 2009;89:193-219. [PMID: 19654034 DOI: 10.1016/j.pneurobio.2009.07.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
336 Kummangal BA, Kumar D, Mallick HN. Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep. Behavioural Brain Research 2013;237:59-62. [DOI: 10.1016/j.bbr.2012.09.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
337 Li A, Nattie E. Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle. J Physiol 2010;588:2935-44. [PMID: 20547681 DOI: 10.1113/jphysiol.2010.191288] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
338 Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 2013;27:83-90. [PMID: 23359095 DOI: 10.1007/s40263-012-0036-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 6.9] [Reference Citation Analysis]
339 Whitman DB, Cox CD, Breslin MJ, Brashear KM, Schreier JD, Bogusky MJ, Bednar RA, Lemaire W, Bruno JG, Hartman GD, Reiss DR, Harrell CM, Kraus RL, Li Y, Garson SL, Doran SM, Prueksaritanont T, Li C, Winrow CJ, Koblan KS, Renger JJ, Coleman PJ. Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats. ChemMedChem 2009;4:1069-74. [PMID: 19418500 DOI: 10.1002/cmdc.200900069] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
340 Laermans J, Depoortere I. Chronobesity: role of the circadian system in the obesity epidemic. Obes Rev 2016;17:108-25. [PMID: 26693661 DOI: 10.1111/obr.12351] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
341 Mignot E. Narcolepsy. Principles and Practice of Sleep Medicine. Elsevier; 2017. pp. 855-872.e7. [DOI: 10.1016/b978-0-323-24288-2.00089-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
342 Fañanás-mastral M, Teichert JF, Fernández-salas JA, Heijnen D, Feringa BL. Enantioselective synthesis of almorexant via iridium-catalysed intramolecular allylic amidation. Org Biomol Chem 2013;11:4521. [DOI: 10.1039/c3ob40655e] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
343 Ueno T, Ishida T, Kusano K. Disposition and metabolism of [ 14 C]lemborexant, a novel dual orexin receptor antagonist, in rats and monkeys. Xenobiotica 2019;49:688-97. [DOI: 10.1080/00498254.2018.1482509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
344 Chung JYL, Zhong Y, Maloney KM, Reamer RA, Moore JC, Strotman H, Kalinin A, Feng R, Strotman NA, Xiang B, Yasuda N. Unusual Pyrimidine Participation: Efficient Stereoselective Synthesis of Potent Dual Orexin Receptor Antagonist MK-6096. Org Lett 2014;16:5890-3. [DOI: 10.1021/ol5028249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
345 Hoch M, Hay JL, Hoever P, de Kam ML, te Beek ET, van Gerven JM, Dingemanse J. Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans. Eur Neuropsychopharmacol 2013;23:107-17. [PMID: 22658401 DOI: 10.1016/j.euroneuro.2012.04.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
346 Martin T, Dauvilliers Y, Koumar OC, Bouet V, Freret T, Besnard S, Dauphin F, Bessot N. Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise. Sci Rep 2019;9:18432. [PMID: 31804545 DOI: 10.1038/s41598-019-54826-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 Ponz A, Khatami R, Poryazova R, Werth E, Boesiger P, Bassetti CL, Schwartz S. Abnormal activity in reward brain circuits in human narcolepsy with cataplexy. Ann Neurol 2010;67:190-200. [DOI: 10.1002/ana.21825] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
348 Williams JT, Gatfield J, Roch C, Treiber A, Jenck F, Bolli MH, Brotschi C, Sifferlen T, Heidmann B, Boss C. Discovery and optimisation of 1-acyl-2-benzylpyrrolidines as potent dual orexin receptor antagonists. Med Chem Commun 2015;6:1054-64. [DOI: 10.1039/c5md00074b] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
349 Lindsay-scott PJ, Gallagher PT. Synthesis of heterocycles from arylacetonitriles: Powerful tools for medicinal chemists. Tetrahedron Letters 2017;58:2629-35. [DOI: 10.1016/j.tetlet.2017.05.089] [Cited by in Crossref: 11] [Article Influence: 2.2] [Reference Citation Analysis]
350 Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med 2016;12:9-17. [PMID: 26194728 DOI: 10.5664/jcsm.5382] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
351 Lee J, Reddy MM, Kodadek T. Discovery Of An Orexin Receptor Positive Potentiator. Chem Sci 2010;1. [PMID: 24409338 DOI: 10.1039/C0SC00197J] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
352 Cruz HG, Hay JL, Hoever P, Alessi F, te Beek ET, van Gerven JM, Dingemanse J. Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine. Eur Neuropsychopharmacol 2014;24:1257-68. [PMID: 24880753 DOI: 10.1016/j.euroneuro.2014.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
353 Lin J, Jiang Y, Wang G, Meng M, Zhu Q, Mei H, Liu S, Jiang F. Associations of short sleep duration with appetite‐regulating hormones and adipokines: A systematic review and meta‐analysis. Obesity Reviews 2020;21. [DOI: 10.1111/obr.13051] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
354 Coborn JE, DePorter DP, Mavanji V, Sinton CM, Kotz CM, Billington CJ, Teske JA. Role of orexin-A in the ventrolateral preoptic area on components of total energy expenditure. Int J Obes (Lond) 2017;41:1256-62. [PMID: 28392556 DOI: 10.1038/ijo.2017.92] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
355 Berger B, Muehlan C, Klein G, Dingemanse J. Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment. Clin Transl Sci 2021. [PMID: 34121345 DOI: 10.1111/cts.13079] [Reference Citation Analysis]
356 Watanabe H, Matsushita N, Shimizu Y, Iikuni S, Nakamoto Y, Togashi K, Ono M. Synthesis and characterization of a novel 18F-labeled 2,5-diarylnicotinamide derivative targeting orexin 2 receptor. Medchemcomm 2019;10:2126-30. [PMID: 32904113 DOI: 10.1039/c9md00397e] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
357 Thannickal TC. A decade of hypocretin/orexin: Accomplishments in sleep medicine. Sleep Medicine Reviews 2009;13:5-8. [DOI: 10.1016/j.smrv.2008.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
358 Chen L, Brown RE, McKenna JT, McCarley RW. Animal models of narcolepsy. CNS Neurol Disord Drug Targets 2009;8:296-308. [PMID: 19689311 DOI: 10.2174/187152709788921717] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
359 Rihel J, Schier AF. Behavioral screening for neuroactive drugs in zebrafish. Dev Neurobiol 2012;72:373-85. [PMID: 21567979 DOI: 10.1002/dneu.20910] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 8.4] [Reference Citation Analysis]
360 Ellenbogen JM, Pace-Schott EF. Drug-induced sleep: theoretical and practical considerations. Pflugers Arch 2012;463:177-86. [PMID: 21953011 DOI: 10.1007/s00424-011-1033-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
361 Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-66. [PMID: 21034217 DOI: 10.1146/annurev-pharmtox-010510-100528] [Cited by in Crossref: 202] [Cited by in F6Publishing: 194] [Article Influence: 18.4] [Reference Citation Analysis]
362 Riemann D, Kloepfer C, Berger M. Functional and structural brain alterations in insomnia: implications for pathophysiology. European Journal of Neuroscience 2009;29:1754-60. [DOI: 10.1111/j.1460-9568.2009.06721.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
363 Holland PR, Goadsby PJ. Cluster headache, hypothalamus, and orexin. Current Science Inc 2009;13:147-54. [DOI: 10.1007/s11916-009-0025-x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 5.0] [Reference Citation Analysis]
364 Dingemanse J, Charef P, Black J, Gouws C. Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects. Biomed Pharmacother 2021;133:110955. [PMID: 33190032 DOI: 10.1016/j.biopha.2020.110955] [Reference Citation Analysis]
365 Palomer A, Príncep M, Guglietta A. Chapter 5 Recent Advances in the Treatment of Insomnia. Annual Reports in Medicinal Chemistry Volume 42. Elsevier; 2007. pp. 63-80. [DOI: 10.1016/s0065-7743(07)42005-x] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
366 Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 2011;25:52-61. [PMID: 21473737 DOI: 10.3109/01677063.2011.566953] [Cited by in Crossref: 179] [Cited by in F6Publishing: 166] [Article Influence: 16.3] [Reference Citation Analysis]
367 Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptors as therapeutic drug targets. Prog Brain Res 2012;198:163-88. [PMID: 22813974 DOI: 10.1016/B978-0-444-59489-1.00010-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 7.1] [Reference Citation Analysis]
368 Gamble MC, Katsuki F, Mccoy JG, Strecker RE, Mckenna JT. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep 2019. [DOI: 10.1093/sleep/zsz241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
369 Tsunematsu T, Kilduff TS, Boyden ES, Takahashi S, Tominaga M, Yamanaka A. Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. J Neurosci 2011;31:10529-39. [PMID: 21775598 DOI: 10.1523/JNEUROSCI.0784-11.2011] [Cited by in Crossref: 152] [Cited by in F6Publishing: 92] [Article Influence: 13.8] [Reference Citation Analysis]
370 Mieda M. The roles of orexins in sleep/wake regulation. Neuroscience Research 2017;118:56-65. [DOI: 10.1016/j.neures.2017.03.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
371 Nishino S. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders. Expert Opinion on Investigational Drugs 2007;16:1785-97. [DOI: 10.1517/13543784.16.11.1785] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
372 Chepke C, Jain R, Rosenberg R, Moline M, Yardley J, Pinner K, Kumar D, Perdomo C, Filippov G, Atkins N, Malhotra M. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder. Postgraduate Medicine. [DOI: 10.1080/00325481.2022.2049553] [Reference Citation Analysis]
373 Xue T, Wu X, Chen S, Yang Y, Yan Z, Song Z, Zhang W, Zhang J, Chen Z, Wang Z. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. Sleep Med Rev 2021;61:101573. [PMID: 34902823 DOI: 10.1016/j.smrv.2021.101573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
374 Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev 2015;35:152-97. [PMID: 25044006 DOI: 10.1002/med.21326] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
375 Faedo S, Perdonà E, Antolini M, di Fabio R, Merlo Pich E, Corsi M. Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists. European Journal of Pharmacology 2012;692:1-9. [DOI: 10.1016/j.ejphar.2012.07.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
376 Beuckmann CT, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. J Pharmacol Exp Ther 2017;362:287-95. [PMID: 28559480 DOI: 10.1124/jpet.117.241422] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
377 Sakurai T, Mieda M, Tsujino N. The orexin system: roles in sleep/wake regulation: Orexin and sleep/wake state. Annals of the New York Academy of Sciences 2010;1200:149-61. [DOI: 10.1111/j.1749-6632.2010.05513.x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 111] [Article Influence: 10.4] [Reference Citation Analysis]
378 Roecker AJ, Mercer SP, Bergman JM, Gilbert KF, Kuduk SD, Harrell CM, Garson SL, Fox SV, Gotter AL, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Bioorganic & Medicinal Chemistry Letters 2015;25:4992-9. [DOI: 10.1016/j.bmcl.2014.12.081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
379 Roecker AJ, Mercer SP, Harrell CM, Garson SL, Fox SV, Gotter AL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis. Bioorganic & Medicinal Chemistry Letters 2014;24:2079-85. [DOI: 10.1016/j.bmcl.2014.03.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
380 Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J. Assessment of the Abuse Liability of a Dual Orexin Receptor Antagonist: A Crossover Study of Almorexant and Zolpidem in Recreational Drug Users. CNS Drugs 2014;28:361-72. [DOI: 10.1007/s40263-014-0150-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
381 Cohen AF. Developing drug prototypes: pharmacology replaces safety and tolerability? Nat Rev Drug Discov 2010;9:856-65. [PMID: 20847743 DOI: 10.1038/nrd3227] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
382 DeCarlo AA, Hammes N, Johnson PL, Shekhar A, Samuels BC. Dual Orexin Receptor Antagonist Attenuates Increases in IOP, ICP, and Translaminar Pressure Difference After Stimulation of the Hypothalamus in Rats. Invest Ophthalmol Vis Sci 2022;63:1. [PMID: 35234838 DOI: 10.1167/iovs.63.3.1] [Reference Citation Analysis]
383 Maehara S, Yuge N, Higashi C, Ota T, Furukawa J, Takeuchi T. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878. Neuropsychopharmacol Rep 2020;40:182-9. [PMID: 32337858 DOI: 10.1002/npr2.12105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
384 Gottlieb E, Egorova N, Khlif MS, Khan W, Werden E, Pase MP, Howard M, Brodtmann A. Regional neurodegeneration correlates with sleep-wake dysfunction after stroke. Sleep 2020;43:zsaa054. [PMID: 32249910 DOI: 10.1093/sleep/zsaa054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
385 Nattie E, Li A. Respiration and autonomic regulation and orexin. Prog Brain Res 2012;198:25-46. [PMID: 22813968 DOI: 10.1016/B978-0-444-59489-1.00004-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
386 Sifferlen T, Boss C, Cottreel E, Koberstein R, Gude M, Aissaoui H, Weller T, Gatfield J, Brisbare-roch C, Jenck F. Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2010;20:1539-42. [DOI: 10.1016/j.bmcl.2010.01.070] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
387 Muehlan C, Zuiker R, Peeters P, Rowles R, Dingemanse J. Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects. J Clin Psychopharmacol 2020;40:157-66. [DOI: 10.1097/jcp.0000000000001182] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
388 Hoch M, Hoever P, Theodor R, Dingemanse J. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin. Eur J Clin Pharmacol 2013;69:1235-45. [PMID: 23334403 DOI: 10.1007/s00228-012-1470-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
389 Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW. Control of sleep and wakefulness. Physiol Rev 2012;92:1087-187. [PMID: 22811426 DOI: 10.1152/physrev.00032.2011] [Cited by in Crossref: 700] [Cited by in F6Publishing: 590] [Article Influence: 70.0] [Reference Citation Analysis]
390 Clark JW, Brian ML, Drummond SP, Hoyer D, Jacobson LH. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Medicine Reviews 2020;53:101332. [DOI: 10.1016/j.smrv.2020.101332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
391 Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Sci Rep 2016;6:27147. [PMID: 27256922 DOI: 10.1038/srep27147] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
392 Brunner JI, Gotter AL, Millstein J, Garson S, Binns J, Fox SV, Savitz AT, Yang HS, Fitzpatrick K, Zhou L, Owens JR, Webber AL, Vitaterna MH, Kasarskis A, Uebele VN, Turek F, Renger JJ, Winrow CJ. Pharmacological validation of candidate causal sleep genes identified in an N2 cross. J Neurogenet 2011;25:167-81. [PMID: 22091728 DOI: 10.3109/01677063.2011.628426] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
393 Kaushik MK, Aritake K, Cherasse Y, Imanishi A, Kanbayashi T, Urade Y, Yanagisawa M. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice. Sleep 2021:zsab043. [PMID: 33609365 DOI: 10.1093/sleep/zsab043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
394 Schwartz TL, Goradia V. Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon. Drugs Context 2013;2013:212257. [PMID: 24432044 DOI: 10.7573/dic.212257] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]